Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, A. M.
Right arrow Articles by Gilboa-Garber, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, A. M.
Right arrow Articles by Gilboa-Garber, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 19, 14017-14024, May 12, 2000


Defining the Carbohydrate Specificities of Aplysia Gonad Lectin Exhibiting a Peculiar D-Galacturonic Acid Affinity*

Albert M. WuDagger §, Shuh-Chyung SongDagger , Yuen-Yuen ChenDagger , and Nechama Gilboa-Garber

From the Dagger  Glyco-Immunochemistry Research Laboratory, Institute of Molecular and Cellular Biology, School of Medicine, Chang-Gung University, Kwei-san 33332, Taiwan and the  Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, 52900, Israel

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Aplysia gonad lectin (AGL), which has been shown to stimulate mitogenesis in human peripheral lymphocytes, to suppress tumor cells, and to induce neurite outgrowth and improve cell viability in cultured Aplysia neurons, exhibits a peculiar galacturonic acid/galactose specificity. The carbohydrate binding site of this lectin was characterized by enzyme-linked lectino-sorbent assay and by inhibition of AGL-glycan interactions. Examination of the lectin binding with 34 glycans revealed that it reacted strongly with the following glycoforms: most human blood group precursor (equivalent) glycoproteins (gps), two Galalpha 1right-arrow4Gal-containing gps, and two D-galacturonic acid (GalUA)-containing polysaccharides (pectins from apple and citrus fruits), but poorly with most human blood group A and H active and sialylated gps. Among the GalUA and mammalian saccharides tested for inhibition of AGL-glycan binding, GalUA mono- to trisaccharides were the most potent ones. They were 8.5 × 104 times more active than Gal and about 1.5 × 103 more active than the human blood group Pk active disaccharide (E, Galalpha 1right-arrow4Gal). This disaccharide was 6, 28, and 120 times more efficient than Galbeta 1right-arrow3GlcNAc(I), Galbeta 1right-arrow3GalNAc(T), and Galbeta 1right-arrow 4GlcNAc (II), respectively, and 35 and 80 times more active than melibiose (Galalpha 1right-arrow6Glc) and human blood group B active disaccharide (Galalpha 1right-arrow3Gal), respectively, showing that the decreasing order of the lectin affinity toward alpha -anomers of Gal is alpha 1right-arrow4 > alpha 1right-arrow6 > alpha 1right-arrow3. From the data provided, the carbohydrate specificity of AGL can be defined as GalUAalpha 1right-arrow4 trisaccharides to mono GalUA > branched or cluster forms of E, I, and II monomeric E, I, and II, whereas GalNAc is inactive.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

The reproductive organs of various molluscs are rich in lectin activity (1, 2). Extracts of gonads and fertilized eggs of Aplysia contain a D-galacturonic acid and D-galactose-binding lectin (1, 2). This lectin (Aplysia gonad lectin, AGL)1 reacts with marine microorganisms (3) and strongly agglutinates human papain-treated erythrocytes regardless of ABO blood groups (2). It was purified by heating to 70 °C, precipitated with ammonium sulfate, and affinity chromatographed on Sepharose 4B (2). The purified lectin is a glycoprotein of molecular mass of about 65 kDa, composed of two identical subunits. It was shown to induce mitogenic stimulation and interleukin-2 formation in human lymphocytes (4), to suppress tumorigenicity of Lewis lung carcinoma cells (5), to modulate neurite outgrowth in cultured Aplysia neurons, and to increase neurite viability in vitro (6). AGL was also shown to be useful for ultrastructural characterization of galacturonic acid in plants and fungi (7) and for differentiation between I and i type human erythrocytes (8). Moreover, it was recently found to be useful for typing of halopilic Archaea and for the study of their S-layer structure (9). Although AGL has been shown to be specific for GalUA and Gal, its detailed carbohydrate specificity has not been established. It is important to elucidate the detailed carbohydrate specificity of this lectin, because it may function as a signaling adhesion molecule and has potential as a tool in experimental glycobiology, biochemistry, and immunochemistry (4-9). In the present study, we defined the glycan affinity of this lectin by both enzyme-linked biotin/avidin-mediated microtiter plate lectin assay (ELLSA) and also by examination of the inhibition of AGL-glycan interaction (10, 11). The great advantage of this method is that the amount of lectin and glycoform required is about 1/10 to 1/1000 of that required for the quantitative precipitin assay (12, 13). The results show that the carbohydrate affinity hierarchy of this lectin can be regarded as: tri-GalUAalpha 1right-arrow4 to mono-GalUA > branched and/or clusters of E(Galalpha 1right-arrow4Gal), I(Galbeta 1right-arrow3GlcNAc), and/or II(Galbeta 1right-arrow4 GlcNAc) monomeric E and I II, although GalNAc is inactive.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Lectin-- The AGL was purified from extracts of the gonads of Aplysia depilans as described previously (2).

Biotinylation of the Lectin-- For AGL biotinylation by biotinamidocaproate-N-hydroxy-succinimide ester (biotin ester, purchased from Sigma), the purified lectin preparation (200 µg/250 µl of phosphate-buffered saline) was mixed with 400 µl of the biotin ester solution (100 µg of biotin ester/200 µg of lectin) and left for 30 min at room temperature. The biotinylated lectin was dialyzed for 2-3 h against distilled H2O and overnight against TBS. After dialysis, the sample volume was adjusted to 1 ml with TBS, and 20 µl of 5% sodium azide was added (200 µg/ml AGL in 0.1% NaN3) (10-11).

Glycoproteins and Polysaccharides-- The blood group substances were purified from human ovarian cyst fluid by the procedures as described previously (14-19). Regardless of their A, B, H, Lea, or Leb activity, the purified water-soluble blood group substances have a similar overall structure. They are polydispersed macromolecules (Mr 2.0 × 105 to 1.0 × 106) of similar composition (75-85% carbohydrates, 15-20% protein). They bear multiple heterosaccharide branches attached by glycosidic linkages at their internal reducing ends to serine or threonine of the polypeptide backbone (14-22).

The P-1 fractions of cyst glycoproteins represent the nondialyzable portion of the blood group substances after mild hydrolysis at pH 1.5-2.0, 100 °C for 2 h, which removed most of the L-fucopyranosyl end groups, as well as some blood group A and B active oligosaccharide side-chains (14, 23, 24). The 1st Smith-degraded products of blood group A active substances (MSS 10% 2X, see Table I), in which almost all of the sugar groups at the nonreducing ends were removed, were prepared as described earlier (18, 20). Both P-1 fractions and 1st Smith degradation products, prepared from human ovarian cyst glycoprotein, are defined as precursor equivalent glycoproteins (Structure I, 25-28).


View larger version (10K):
[in this window]
[in a new window]
 
Structure I.   Proposed carbohydrate side chains of blood group active glycoproteins prepared from human ovarian cyst fluid. The blood group substance was purified from human ovarian cyst fluid by digestion with pepsin and precipitation with ethanol; the dried ethanol precipitates were extracted with 90% phenol, the insoluble fraction being given after the name of the blood group substance (e.g. Cyst Beach phenol insoluble). The supernatant was fractionally precipitated by the addition of 50% ethanol in 95% phenol to the indicated concentrations. The designation 10 or 20%(ppt) denotes a fraction precipitated from phenol at an ethanol concentration of 10 or 20%; 2X signifies that a second phenol extraction from ethanol precipitation was carried (e.g. Cyst OG 20% 2×). The 4-branched structure (I---IV) shown above represents the internal portion of the carbohydrate moiety of blood group substances to which the residues responsible for A, B, H, Lea, and Leb activities are attached. This structure represents precursor blood group active glycoproteins (25) and the precursor equivalent gp can be prepared by Smith degradation of cyst A, B, and H active glycoproteins (4, 19, 20, 22, 25) or mild acid hydrolysis (P-1 gp) (4, 12, 23, 24). Numbers in parentheses indicate the site of attachment for the human blood group A, B, H, Lea, and Leb determinants. These determinants as well as the structural units at the nonreducing end are the sources of lectin A/Ah, B, I, II, T, and Tn determinants. A megalo-saccharide of 24 sugars has not been isolated. However, most of the carbohydrate chains isolated are parts of this structure. For this structure, various human blood group determinants are attached and illustrated in Table I.

The human blood group P1-active substance, purified from sheep hydatid cyst glycoprotein (29, 30), was kindly provided by Dr. W. M. Watkins (University of London, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK). The mucus glycoprotein (native bird nest glycoprotein), the so-called nest-cementing substance (Structure II), from the salivary gland of Chinese swiftlets (genus Collocalia), was extracted with distilled H2O at 60 °C for 20 min from the commercial bird nest substance (Kim Hing Co., Singapore) (31, 32).


<AR><R><C><UP>Gal&agr;1→4Gal&bgr;1→4Gal&bgr;1→4GlcNAc  </UP></C></R><R><C><UP>
                   ↓&bgr;1,6</UP></C></R><R><C><UP>
            Gal&bgr;1→3GalNAc-ol</UP></C></R><R><C><UP>
             ↑&agr;2,3</UP></C></R><R><C><UP>
            NeuAC</UP></C></R></AR>

<UP>and</UP>

<AR><R><C><UP>Gal&agr;1→4Gal&bgr;1→4Gal&bgr;1→4GlcNAc</UP></C></R><R><C><UP>
                   ↓&bgr;1,6</UP></C></R><R><C><UP>
            Gal&bgr;1→3GalNAc&agr;1→3GalNAc-ol</UP></C></R><R><C><UP>
             ↑&agr;2,3</UP></C></R><R><C><UP>
            NeuAc   </UP></C></R></AR>

The mucus glycoproteins, the so-called nest-cementing substances, from the salivary gland of Chinese swiftlets (genus Collocalia) are mainly constituted of sialic acid-rich O-glycosylproteins (31, 32). The most complex representatives of the monosialyl fraction from Collocalia mucin are shown. The other compounds identified are partial structures thereof.

Structure II.  

The Pneumococcus type XIV polysaccharide was prepared as described previously (33, 34). Fetuin (Life Technologies, Inc.), which is the major glycoprotein in fetal calf serum (35), has a molecular mass of 48,400 with the following composition: 78% amino acids, 8.7% sialic acid, 6.3% hexosamines, and 8.3% neutral sugars (36). It bears six oligosaccharide side chains/molecule, three of them (of two types) are O-glycosyl-linked to Ser or Thr residues of the protein core, and the other three are N-glycosyl-linked to asparagine (37-39).

The rat sublingual glycoprotein (RSL) was prepared by the method of Moschera and Pigman (40). Its molecular mass is 2.2 × 106 and it contains 81% carbohydrates (40). The carbohydrate side-chains (Structure III) are O-glycosyl-linked to Ser or Thr residues of the protein core. The established structure has 9, 10, 12, 13, and 15 sugar residues with NeuNAcalpha 2,6 linked to Gal, GalNAcalpha 1right-arrowSer/Thr (Tn), and GlcNAc groups at the nonreducing ends, as well as a repeating unit, Galbeta 1right-arrow4GlcNAcbeta 1right-arrow, in the carbohydrate core structure (Structure III) (41). It was found that its carbohydrate chains also contain the Tn active determinant (42).


<UP>One </UP><UP>GlcNAc&bgr;1→3Gal&bgr;1→4GlcNAc&bgr;1→3Gal&bgr;1→4GlcNAc&bgr;1→3Gal&bgr;1→4GlcNAc</UP>

<UP>&bgr;1→3Gal&bgr;1→4GlcNAc&bgr;1→3GalNAc</UP>

<UP>Two </UP><UP>GlcNAc&bgr;1→3Gal&bgr;1→4GlcNAc&bgr;1→3Gal&bgr;1→4GlcNAc&bgr;1→3Gal&bgr;1→4GlcNAc&bgr;1→3GalNAc</UP>

<UP>Two </UP><UP>GlcNAc&bgr;1→3Gal&bgr;1→4GlcNAc&bgr;1→3Gal&bgr;1→4GlcNAc&bgr;1→3GalNAc</UP>

Established structure of the carbohydrate moiety of asialo rat sublingual glycoprotein contains the following chains of three different lengths. Most of the carbohydrate chains are parts of this structure (40, 41). Furthermore, variations in this ratio and in chain lengths are expected to occur in different mucin preparations (42).

Structure III.  

Porcine salivary mucin (PSM), bovine submandibular glycoprotein-major, and armadillo salivary glycoprotein were purified according to the method of Tettamanti and Pigman (43) with some modifications (44-47). Sialic acids were removed from sialylated glycoproteins by mild acid hydrolysis with 0.01 N HCl at 80 °C for 90 min and dialyzed against distilled water for 2 days to remove small fragments (47).

Hog gastric mucin 4 (48) and its mild acid degraded products (Hog gastric mucin 9, Hog gastric mucin 14, and Hog gastric mucin 21) were prepared according to the method previously described (49). Human alpha 1-acid glycoprotein (50, 51) and pectins from apple and citrus fruits were purchased from Sigma.

Monosaccharides and Oligosaccharides Used for Inhibition Assay-- GalUA, GalUAalpha 1right-arrow4GalUA, GalUAalpha 1right-arrow4GalUAalpha 1right-arrow4GalUA, and all other sugar ligands were purchased from Sigma.

The Microtiter Plate Lectin-Enzyme Binding Assay (ELLSA)-- ELLSA was performed according to the procedures of Duk et al. (10) or as described previously (12, 13). The volume of each reagent applied to the plate was 50 µl/well, and all incubations, except for coating, were performed at 20 °C. The reagents, if not otherwise indicated, were diluted with TBS containing 0.05% Tween 20. The TBS buffer or 0.15 M NaCl containing 0.05% Tween 20 was used for washing the plates between incubations.

For inhibition studies, the serially diluted inhibitor samples were mixed with an equal volume of lectin solution containing a fixed amount of lectin. The control lectin sample was diluted 2-fold with TBS containing 0.05% Tween 20. After 30 min at 20 °C, the samples were tested in the binding assay, as described above. The inhibitory activity was estimated from the inhibition curve and expressed as the amount of inhibitor (nmol/well) giving 50% inhibition of the control lectin binding.

All experiments were done in duplicate or triplicate, and the data presented are mean values of the results. The standard deviation did not exceed 10% and in most experiments was less than 5% of the mean value. The control wells, where either coating or addition of biotinylated lectin was omitted, gave low absorbance values (below 0.1, read against the well filled with buffer) and were used as blank. It has been shown that blocking the wells before lectin addition was not necessary when Tween 20 was used in TBS.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Lectin-Glycan Interactions-- The avidity of AGL for gps and polysaccharides, as studied by a microtiter plate ELLSA, is summarized in Table II according to the interaction profiles shown in Fig. I. AGL reacted most strongly with five human blood group precursor-equivalent gps related to Structure I (Cyst OG, Cyst Mcdon P-1, and Cyst MSS 1st Smith in Fig. 1c; Cyst Beach P-1 in Fig. 1d; and Cyst Tighe P-1 in Fig. 1e), two Galalpha 1right-arrow4Gal-containing gps (asialo bird nest gp and sheep hydatid cyst gp, Fig. 1b), and two GalUA-containing fruit polysaccharides (pectin A from apple and pectin C from citrus, Fig. 1a). AGL also bound well asialo rat sublingual gp (Fig. 1h), blood group B active gp from human ovarian cyst fluid (Cyst Tij, Fig. 1d), and asialo PSM (Fig. 1i). Because the percentage of glycans adsorbed onto the microtiter plate had not been established, the amount of glycans required to reach maximum interaction could not be evaluated. However, their binding reactivities were confirmed by the inhibition of AGL-glycan interaction with various glycans, as described under "Inhibition of AGL-Glycoform Interaction by Various Glycans" (Fig. 2 and Table III).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Identification of the curves from Structure I


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 1.   Binding of AGL to microtiter plates coated with serially diluted human blood group A, B, O, P1, Leb, and Ii active glycoproteins, sialo and asialo glycoproteins and polysaccharides. The lectin was used at a constant amount of 5 ng/well. Total volume 50 µl. A405 was recorded after 2 h of incubation.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   Inhibition of AGL binding to Cyst Beach P-1-coated enzyme-linked immunosorbent assay plates with various glycoproteins and Tn-containing glycopeptides. The quantity of Cyst Beach P-1 in the coating solution was 10 ng/well. The quantity of lectin used for inhibition assay was 5 ng/well. Total volume, 50 µl. A405 was recorded after a 2-h incubation. When 277.8 ng of glycoprotein were used to inhibit AGL-Beach P-1 glycoprotein binding, the concentration required to induce 50% inhibition was determined. In this assay, Hog gastric mucin 4; Hog gastric mucin 9; Cyst MSS 10% 2x; Cyst Mcdon; PSM; Cyst JS phenol insoluble; Cyst Tighe phenol insoluble; RSL; fetuin; asialo fetuin; bovine submandibular gp-major; asialo bovine submandibular gp-major; OSM; asialo OSM (curves 22 to 35) did not reach 50% inhibition.

Except the bird nest gp [Fig. 1b], the blood group A, B, H or Leb substances and mammalian salivary gps containing Galbeta 1right-arrow4GlcNAc and Galbeta 1right-arrow3GalNAc masked by sialic acids were either weakly active or inactive (Fig. 1 and Table II). These included cyst MSS 10% 2x(A1) (Fig. 1c), cyst Mcdon (A1) (Fig. 1c), cyst JS phenol insoluble(H) (Fig. 1e), cyst Tighe phenol insoluble (H+Leb) (Fig. 1e); hog gastric mucin 4 (A+H) (Fig. 1f), rat sublingual gp (Fig. 1h), and PSM (Fig. 1i). Neither native salivary gps nor asialo products containing exposed Tn determinants only (Fig. 1i) reacted with AGL.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Binding of AGL lectin to human blood group A, B, H, P1 and Leb active glycoproteins (gps), sialo- and asialo glycoproteins by ELLSA
5 ng of biotinylated lectin was added to glycoprotein concentrations ranging from 0.12 to 10 µg.

Inhibition of AGL-Glycoform Interaction by Various Glycans-- The abilities of various glycans to inhibit the binding of AGL with Cyst Beach P-1 glycoprotein by ELLSA were analyzed and are shown in Fig. 2 and Table III. Among the glycans tested for inhibition of that interaction, six human blood group precusor equivalent gps (curves 1, 5, 6, 9, 10, and 11 in Fig. 2 and Table III); two Galalpha 1right-arrow4Gal containing glycoproteins (sheep hydatid cyst gp and asialo bird nest, curves 3 and 4 of Fig. 2 and Table III), and two GalUA-containing polysaccharides (pectin-A and pectin-C, curves 7 and 8 of Fig. 2 and Table III) were the best inhibitors, requiring less than 12 ng to inhibit 50% of the interaction. They were much more active than monomeric Galalpha 1right-arrow4Gal and Gal but much weaker than GalUA (Fig. 2 and Table III). The precursor equivalent and asialo glycoproteins were much more active than their further glycosylated, native or sialylated compounds (curve 4 versus curve 19, curves 5 and 6 versus corresponding native compounds in Fig. 2 and Table III, etc.). The decreasing order of the reactivity of these glycoforms is Cyst OG 10% 2x PPT (one of the human blood group precursor gps, Structure I, curve 1 in Fig. 2) and sheep hydatid cyst gp (blood group P1 active gp) (curve 3 in Fig. 2) > asialo bird nest gp (curve 4), five human blood group precursor gps (curves 5, 6, 9, 10, and 11) and two GalUA-containing gps; pectin-A and pectin-C (curves 7 and 8) > a blood group B active gp (curve 12); mild acid-hydrolyzed hog gastric mucin 14 (II), hog mucin 21 (II), and asialo rat sublingual gp (II, structure III) blood group A and H active glycoproteins and sialylated glycoproteins (Figs. 2 and 4). With several exceptions, the inhibitory reactivities of glycoforms toward AGL agree, in general, with the maximum absorbance values recorded in the binding assay (Fig. 1 and Table II).

                              
View this table:
[in this window]
[in a new window]
 
Table III
Amount of various glycoproteins giving 50% inhibition of AGL (5 ng/50 µl)-Cyst Beach P 1 gp (10 ng/50 µl) binding
The inhibitory activity was estimated from the respective inhibition curve in Fig. 2 and is expressed as the amount of inhibitor (nanogram) giving 50% inhibition. Total volume 50 µl. GalUA: 4 × 103 nanogram is equal to 2 ×10-5 nmol, Galalpha 1right-arrow4Gal: 850 nanograms is equal to 2.5 nmol, Gal: 7 × 103 nanograms is equal to 3.9 × 10-2 nmol. Glycans that did not reach 50% inhibition are described in the legend to Fig. 2.

The weak or negative reactivity of AGL with A and H active gps and most sialylated gps (Cyst Mcdon and Cyst MSS (Fig. 1c), Cyst Beach phenol insoluble (Fig. 1d), Cyst Tighe phenol insoluble (Fig. 1e)), human alpha 1-acid gp (Fig. 1g), RSL (Fig. lh), and PSM (Fig. 1i)) could be ascribed to the masking effects of LFucalpha 1right-arrow, GalNAcalpha 1right-arrow, and sialic acid at the terminal Galbeta 1right-arrow and/or poor adsorbance of these glycoforms onto a microwell plate.

Mild acid hydrolysis (pH 1.5, 100 °C for 2 h), which removes the terminal L-Fucalpha 1right-arrow linked and some blood group A and B active oligosaccharide side chains (14-17), and Smith degradation, which removes almost all nonreducing terminal sugars, should significantly increase their interactions with this lectin (Tables II and III and Figs. 1 and 2) (18). The Galbeta 1right-arrow determinant of human blood group precursor or precusor equivalent gp (Structure I) is similar to Bombay type erythrocytes (Oh) that are more strongly agglutinated by this lectin than the O(H) blood type (8).

Inhibition of Lectin-Glycan Interaction by Mono- and Oligosaccharides-- The ability of various sugars to inhibit the binding of AGL to cyst Beach P-1 gp (human blood group precursor equivalent gp purified from human ovarian cyst fluid) is shown in Fig. 3, and the amounts of ligand required for 50% inhibition of the lectin-glycan interaction are listed in Table IV. Among the oligo- and monosaccharides tested, di > tri-GalUAalpha 1right-arrow4 to mono-GalUA were the most active, up to 8.5 × 104 times more active than Gal, indicating that COOH at carbon-6 is the most important factor for binding. GalUA was about 1.5 × 103 times more active than human blood group Pk active disaccharides (E, Galalpha 1right-arrow4Gal), which was 6, 28, and 120 times more active than Galbeta 1right-arrow3GlcNAc(I), Galbeta 1right-arrow3GalNAc(T), and Galbeta 1right-arrow4GlcNAc (II), respectively. These results, show that each lectin has its own binding characteristics (26-28) and that the carbohydrate specificity of AGL can be defined as GalUAalpha 1right-arrow4 di > trisaccharides to mono GalUA > branched or cluster forms of E, I, and II monomeric E(Galalpha 1right-arrow4Gal) I(Galbeta 1right-arrow3GlcNAc) > T(Galbeta 1right-arrow3GalNAc) > B(Galalpha 1right-arrow3Gal) II(Galbeta 1right-arrow4GlcNAc), and L(lactose).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of AGL binding to human cyst Beach P-1 (human blood group precusor equivalent) gp-coated enzyme-linked immunosorbent assay plates by various saccharides. The amount of glycoproteins in the coating solution was 10 ng/well. The lectin (10 ng/well) was preincubated with an equal volume of serially diluted inhibitor. The final lectin content was 5 ng/well. Total volume, 50 µl. A405 was recorded after 2 h of incubation. The following sugar inhibitors were tested from 80 to 556 nmol and found to be inactive-GalNAc, L-Ara, GlcNAc, Glc, methyl-alpha -Glc, methyl-beta -Glc, p-NO2-phenyl-alpha -GalNAc, GlcNAcbeta 1right-arrow4GlcNAc, and GalNAcbeta 1right-arrow 3Gal-O-methyl.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Amount of various saccharides giving 50% inhibition of AGL binding (5 ng/50 µl) to Cyst Beach P-1 gp (10 ng/50 µl)
The inhibitory activity was estimated from the inhibition curve in Fig. 3 and is expressed as the amount of inhibitor giving 50% inhibition. Total volume 50 µl.

Galbeta 1right-arrow4Man was about 2.5 times less active than Galbeta 1right-arrow3GlcNAc (I), but 6.7 and 8 times more active than Galbeta 1right-arrow4Glc(L) and Galbeta 1right-arrow4GlcNAc (II), respectively. These results show that the configuration at C-2 in the subterminal hexopyranose is also important for the binding and that substitution with -NHCOCH3 at C-2 reduces the inhibitory power. Melibiose and raffinose (Galalpha 1right-arrow6Galbeta 1right-arrow2DFructo-furanoside) were almost equally active and 4.0 times more active than stachyose (Galalpha 1right-arrow6Galalpha 1right-arrow6Glcbeta 1right-arrow2DFructofuranoside), suggesting that the combining size for alpha 1right-arrow6 oligosaccharides is probably most accessible with less than a trisaccharide structure.

Among alpha -anomers of Gal tested, Galalpha 1right-arrow4Gal was 35 and 80 times more active than melibiose (Galalpha 1right-arrow6Glc) (curve 10 in Fig. 3a and Table IV) and Galalpha 1right-arrow3Gal (curve 21 in Fig. 3b and Table IV), respectively. Hence, the decreasing order of preference of the lectin for alpha -anomers of Gal is: alpha 1right-arrow4 > alpha 1right-arrow6 > alpha 1right-arrow3.

Of the monosaccharide derivatives studied, phenylbeta Gal (Fig. 3a, curve 9) was the best inhibitor 2 × 104 times less active than GalUA (Fig. 3b, curve 3), but 1.8 times more active than Gal and 1.2 times more than p-NO2-phenylbeta Gal and p-NO2-phenylalpha Gal. As shown in Table IV, the phenylalpha -derivative of Gal was about 2 times better than the methyl-alpha -derivative (Fig. 3, curves 13 versus 20), whereas no significant difference was observed between the methyl- and p-NO2phenyl derivatives of beta -Gal (Fig. 3a, curves 12 and 14).

GalNAc, which was tested up to a concentration exceeding that of Gal inducing 50% inhibition by 2.4-fold (Fig. 3 and Table IV), was inactive indicating that the N-acetamido group at C-2 of the Gal pyranose ring strongly interferes with its interaction with AGL. D-Fuc and L-Ara showed no inhibition up to three times the amount of Gal giving 50% inhibition, suggesting that the OH group at C-6 or the CH2OH at C-6 of Gal is essential for lectin binding. GlcNAc, Glc, methyl-alpha -Glc, and methyl-beta -Glc were tested at concentrations from 380 to 463 nmol, but no inhibition of lectin binding was observed.

From these assays, we conclude that the major contributions of this study are: 1) establishment of the binding relationship between AGL and mammalian carbohydrate structural units; 2) illustration of the high specificity of AGL for GalUA-related glycotopes, which is rare and is an important consideration in animal lectins; 3) demonstration that the COO- group rather than OH- at carbon-6 dramatically enhances binding reactivity; and 4) presentation that the presence of carboxylated (-COOH) or hydroxylated (-OH) carbon-6 and the configuration of Gal at carbon-4 are essential for binding (Gal versus Glc). This information should be useful for elucidating the mechanism of adhesion in the life process of Aplysia and other aspects of glycobiology.

    FOOTNOTES

* This work was supported by Grant 676 from the Chang-Gung Medical Research Project, Kwei-san, Tao-yuan, Taiwan and Grants 86-2316-B182-001-BC and 84-2811-B182-001R from the National Science Council, Taipei, Taiwan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Glyco-Immunochemistry Research Laboratory, Inst. of Molecular and Cellular Biology, Chang-Gung Medical College, Kwei-san 333, Taiwan. Tel.: 886-3-328-6966; Fax: 886-3-328-6456 (laboratory) or 886-3-328-3031 (college); E-mail: amwu@mail.cgu.edu.tw.

    ABBREVIATIONS

The abbreviations used are: AGL, Aplysia gonad lectin; GalUA, D-galacturonic acid; Gal, D-galactopyranose; ELLSA, enzyme-linked lectino-sorbent assay; TBS, Tris-buffered saline; Glc, D-glucopyranose; GlcNAc, 2-acetamido-2-deoxy-D-glucopyranose; PSM, porcine salivary gp major; LFuc or Fuc, L-fucopyranose; GalNAc, 2-acetamido-2-deoxy-D-galactopyranose; gp, glycoprotein; RSL, rat sublingual gp major; OSM, ovine submandibular gp major; BSM, bovine salivary gp major; NeuNAc, N-acetylreuraminic acid. Lectin determinants that are used to classify applied lectins are expressed in bold: A (GalNAcalpha 1right-arrow3Gal), Ah (GalNAcalpha 1right-arrow3[LFucalpha 1right-arrow2]Gal), B (Galalpha 1right-arrow 3Gal), T (Galbeta 1right-arrow 3GalNAc), I/II (Galbeta 1right-arrow3/4GlcNAc), F (GalNAcalpha 1right-arrow3GalNAc), L (Galbeta 1right-arrow4Glc), Tn (GalNAcalpha 1right-arrow Ser/Thr), E (Galalpha 1right-arrow4Gal, the human blood group Pk active disaccharide, which is also part of P1 determinant, but this disaccharide is not the key sequence for its reactivity) (26-28).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Gilboa-Garber, N., Mizrahi, L., and Susswein, A. J. (1984) Mar. Biol. Lett. 5, 105-114
2. Gilboa-Garber, N., Susswein, A. J., Mizrahi, L., and Avichezer, D. (1985) FEBS Lett. 181, 267-270[CrossRef][Medline] [Order article via Infotrieve]
3. Zipris, D., Gilboa-Garber, N., and Susswein, A. J. (1986) Microbios. 46, 193-198[Medline] [Order article via Infotrieve]
4. Zipris, D., and Gilboa-Garber, N. (1987) Develop. Comp. Immunol. 11, 501-511[CrossRef][Medline] [Order article via Infotrieve]
5. Avichezer, D., Leibovici, J., Gilboa-Garber, N., and Michowitz, M. (1987) in Lectures and Symposia 14th International Cancer Cong. Budapest, 1986 (Lapis, K. , and Ackhardt, S., eds), Vol. 2 , pp. 79-86, Karger, Basel, New York
6. Wilson, M. P., Carrow, G. M., and Levitan, I. B. (1992) J. Neurobiology 23, 739-750[CrossRef][Medline] [Order article via Infotrieve]
7. Benhamou, N., Gilboa-Garber, N., Trudel, J., and Asselin, A. (1988) J. Histochem. Cytochem. 36, 1403-1412[Abstract]
8. Sudakevitz, D., Levene, C., and Gilboa-Garber, N. (1996) in Lectins: Biology, Biochemistry, Clinical Biochemistry (Van Driessche, E. , Rougé, P. , Beeckmans, S. , and Bøg-Hansen, T. C., eds), Vol. 11 , pp. 207-211, Textop Hellerup, Denmark
9. Gilboa-Garber, N., Mymon, H., and Oren, A. (1998) FEMS Microbiol. Lett. 163, 91-97[CrossRef][Medline] [Order article via Infotrieve]
10. Duk, M., Lisowska, E., Wu, J. H., and Wu, A. M. (1994) Anal. Biochem. 221, 266-272[CrossRef][Medline] [Order article via Infotrieve]
11. Lisowska, E., Duk, M., and Wu, A. M. (1996) BioMethods 7, 115-129
12. Wu, A. M., Song, S. C., Chang, S. C., Wu, J. H., Chang, K. S. S., and Kabat, E. A. (1997) Glycobiology 7, 1061-1066[Abstract/Free Full Text]
13. Chen, C. P., Song, S. C., Gilboa-Garber, N., Chang, K. S. S., and Wu, A. M. (1998) Glycobiology 8, 7-16[Abstract/Free Full Text]
14. Beiser, S. M., and Kabat, E. A. (1952) J. Immunol. 68, 19-40
15. Kabat, E. A. (1956) Blood Group Substances. Their Chemistry and Immunochemistry , pp. 135-139, Academic Press, New York
16. Allen, P. Z., and Kabat, E. A. (1959) J. Immunol. 82, 340-357
17. Vicari, G., and Kabat, E. A. (1969) J. Immunol. 102, 821-825[Abstract/Free Full Text]
18. Lloyd, K. O., and Kabat, E. A. (1968) Proc. Natl. Acad. Sci. U. S. A. 61, 1470-1477[Free Full Text]
19. Maisonrouge-McAuliffe, F., and Kabat, E. A. (1976) Arch. Biochem. Biophys. 175, 81-89[CrossRef][Medline] [Order article via Infotrieve]
20. Wu, A. M., Kabat, E. A., Pereira, M. E. A., Gruezo, F. G., and Liao, J. (1982) Arch. Biochem. Biophys. 215, 390-404[CrossRef][Medline] [Order article via Infotrieve]
21. Vicari, G., and Kabat, E. A. (1970) Biochemistry 9, 3414-3421[CrossRef][Medline] [Order article via Infotrieve]
22. Wu, A. M., Kabat, E. A., Nilsson, B., Zopf, D. A., Gruezo, F. G., and Liao, J. (1984) J. Biol. Chem. 259, 7178-7186[Abstract/Free Full Text]
23. Kabat, E. A., Baer, H., Bezer, A. E., and Knaub, V. (1948) J. Exp. Med. 88, 43-57[Abstract]
24. Leskowitz, S., and Kabat, E. A. (1954) J. Am. Chem. Soc. 76, 5060-5065[CrossRef]
25. Wu, A. M. (1988) Adv. Exp. Med. Biol. 228, 351-394[Medline] [Order article via Infotrieve]
26. Wu, A. M., and Sugii, S. (1991) Carbohydr. Res. 213, 127-143[CrossRef]
27. Wu, A. M., and Sugii, S. (1988) Adv. Exp. Med. Biol. 228, 205-263[Medline] [Order article via Infotrieve]
28. Wu, A. M., Song, S. C., Sugii, S., and Herp, A. (1997) Ind. J. Biochem. Biophys. 34, 61-71[Medline] [Order article via Infotrieve]
29. Cory, H. T., Yates, A. D., Donald, A. S., Watkin, W. M., and Morgan, W. T. J. (1974) Biochem. Biophys. Res. Commun. 61, 1289-1296[CrossRef][Medline] [Order article via Infotrieve]
30. Morgan, W. T. J., and Watkins, W. M. (1964) Proceedings of the 9th Congr. International Society for Blood Transfusion, Mexico 1962, pp. 225-229
31. Wieruszeski, J. M., Michalski, J. C., Montreuil, J., Strecker, G., Peter-Katalinic, J., Egge, H., van Halbeek, H., Mutsaers, J. H. G. M., and Vliegenthart, J. F. G. (1987) J. Biol. Chem. 262, 6650-6657[Abstract/Free Full Text]
32. Wu, A. M., Song, S.-C., Hwang, P.-Y., Wu, June, H., and Kabat, E. A. (1995) Biochem. Biophys. Res. Commun. 216, 814-820[CrossRef][Medline] [Order article via Infotrieve]
33. Lindberg, B., Lonngren, J., and Powell, D. A. (1977) Carbohydr. Res. 58, 177-186[CrossRef][Medline] [Order article via Infotrieve]
34. Howe, C., Schiffman, G., Bezer, A. E., and Kabat, E. A. (1958) J. Am. Chem. Soc. 80, 6656-6661[CrossRef]
35. Spiro, R. G., and Bhoyroo, V. D. (1974) J. Biol. Chem. 249, 5704-5717[Abstract/Free Full Text]
36. Graham, E. R. B. (1972) in Glycoproteins (Gottschalk, A., ed), 2nd Ed. , pp. 722-723, Elsevier, Amsterdam
37. Nilsson, B., Norden, N. E., and Svensson, S. (1979) J. Biol. Chem. 254, 4545-4553[Free Full Text]
38. Townsend, R. R., Hardy, M. R., Wong, T. C., and Lee, Y. C. (1986) Biochemistry 25, 5716-5725[CrossRef][Medline] [Order article via Infotrieve]
39. Edge, A. S. B., and Spiro, R. G. (1987) J. Biol. Chem. 262, 16135-16141[Abstract/Free Full Text]
40. Moschera, J., and Pigman, W. (1975) Carbohydr. Res. 40, 53-67[CrossRef][Medline] [Order article via Infotrieve]
41. Slomiany, A., and Slomiany, B. L. (1978) J. Biol. Chem. 253, 7301-7306[Abstract/Free Full Text]
42. Wu, A. M., Herp, A., Song, S. C., Wu, J. H., and Chang, K. S. S. (1995) Life Sci. 57, 1841-1852[CrossRef][Medline] [Order article via Infotrieve]
43. Tettamanti, G., and Pigman, W. (1968) Arch. Biochem. Biophys. 124, 41-50[CrossRef][Medline] [Order article via Infotrieve]
44. Herp, A., Wu, A. M., and Moschera, J. (1979) Mol. Cell. Biochem. 23, 27-44[CrossRef][Medline] [Order article via Infotrieve]
45. Herp, A., Borelli, C., and Wu, A. M. (1988) Adv. Exp. Med. Biol. 228, 395-435[Medline] [Order article via Infotrieve]
46. Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J. F. G., Binette, J. P., and Schmid, K. (1978) Biochemistry 17, 5206-5214[CrossRef][Medline] [Order article via Infotrieve]
47. Wu, A. M., and Pigman, W. (1977) Biochem. J. 161, 37-47[Medline] [Order article via Infotrieve]
48. Van Halbeek, H., Dorland, L., Vliegenthart, J. F. G., Kochetkov, N. K., Arbatsky, N. P., and Derevitskaya, V. A. (1982) Eur. J. Biochem. 127, 21-29[Medline] [Order article via Infotrieve]
49. Wu, A. M., Lin, S.-R., Chin, L.-K., Chow, L.-P., and Lin, J.-Y. (1992) J. Biol. Chem. 267, 19130-19139[Abstract/Free Full Text]
50. Schmid, K., Binette, J. P., Dorland, L., Vliegenthart, J. F. G., Fournet, B., and Montreuil, J. (1979) Biochim. Biophys. Acta 581, 356-359[Medline] [Order article via Infotrieve]
51. Fournet, B., Montreuil, J., Strecker, G., Dorland, L., Haverkamp, J., Vliegenthart, J. F. G., Binette, J. P., and Schmid, K. (1978) Biochemistry 17, 5206-5214


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
GlycobiologyHome page
A. M. Wu, T. Singh, J. H. Wu, M. Lensch, S. Andre, and H.-J. Gabius
Interaction profile of galectin-5 with free saccharides and mammalian glycoproteins: probing its fine specificity and the effect of naturally clustered ligand presentation
Glycobiology, June 1, 2006; 16(6): 524 - 537.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
T. Singh, U. Chatterjee, J. H. Wu, B. P. Chatterjee, and A. M. Wu
Carbohydrate recognition factors of a T{alpha} (Gal{beta}1->3GalNAc{alpha}1->Ser/Thr) and Tn (GalNAc{alpha}1->Ser/Thr) specific lectin isolated from the seeds of Artocarpus lakoocha
Glycobiology, January 1, 2005; 15(1): 67 - 78.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, A. M.
Right arrow Articles by Gilboa-Garber, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, A. M.
Right arrow Articles by Gilboa-Garber, N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement